Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.49 |
| ▸ | ELANE | P08246 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | THRA | P10827 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | VDR | P11473 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4265674 | 0.91 | ALDH1A1 (0.51) | PLAUSMN1; SMN2ALDH1A1MAPTTP53 | |
| SCHEMBL4266277 | 0.84 | KDM4E (0.57) | PLAUSMN1; SMN2ALDH1A1MAPTTP53 | |
| SCHEMBL4264131 | 0.83 | PLAU (0.52) | PLAUELANECYP3A4SMN1; SMN2ALDH1A1 | |
| SCHEMBL4256127 | 0.81 | ALDH1A1 (0.54) | SMN1; SMN2ALDH1A1TP53MAPK1KDM4E | |
| Hydrochloric Acid SCHEMBL4260464 | 0.80 | ALDH1A1 (0.53) | SMN1; SMN2ALDH1A1TP53MAPK1KDM4E | |
| SCHEMBL4261704 | 0.79 | ALDH1A1 (0.55) | CYP3A4SMN1; SMN2ALDH1A1MAPTTP53 | |
| SCHEMBL4261815 | 0.79 | PTPN1 (0.47) | SMN1; SMN2ALDH1A1MAPK1KDM4EHPGD | |
| SCHEMBL4259275 | 0.79 | RAB9A (0.53) | CYP3A4SMN1; SMN2ALDH1A1MAPTTP53 | |
| SCHEMBL4266379 | 0.78 | ALDH1A1 (0.44) | SMN1; SMN2ALDH1A1MAPTTP53ESR1 | |
| SCHEMBL4257919 | 0.77 | SMN1; SMN2 (0.58) | SMN1; SMN2ALDH1A1MAPTTP53VDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029995-A1 | HETERO BIARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2009-01-29 | — | — | US | disclosed |
| US-20090029995-A1 | HETERO BIARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2009-01-29 | — | — | US | disclosed |
| US-20090029995-A1 | HETERO BIARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2009-01-29 | — | — | US | disclosed |
| US-7179822-B2 | Hetero biaryl derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179822-B2 | Hetero biaryl derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179822-B2 | Hetero biaryl derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-02-20 | — | — | US | disclosed |
| EP-1536784-A1 | HETERO BIARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20040048863-A1 | Hetero biaryl derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2004014366-A1 | HETERO BIARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029995-A1 | HETERO BIARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | MMP9, MMP2, MMP3 | PLAU 49/4885ELANE 132/4885CYP3A4 604/4885 |
| US-20040048863-A1 | Hetero biaryl derivatives as matrix metalloproteinase inhibitors | MMP13, MMP11, MMP9 | PLAU 238/4885ELANE 706/4885CYP3A4 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.